| Baseline/Start Rx |  |  |  |  |  | End of treatment |  |
---|---|---|---|---|---|---|---|---|
Week | Â | 1 | 2 | 3 | 6 | 9 | 12 | 24 |
Study measures | Â | Â | Â | Â | Â | Â | Â | Â |
Sociodemographic characteristics | X | Â | Â | Â | Â | Â | Â | Â |
Tobacco use behavior, FTNDa | X | Â | Â | X | X | X | X | X |
Smoking endpointsb | Â | Â | Â | X | X | X | X | X |
Medication adherence | Â | X | X | X | X | X | X | Â |
Mini-International Neuropsych. Interview | X | Â | Â | X | X | X | X | X |
Modified scale for suicidal ideation | X | Â | Â | X | X | X | X | Â |
Brief symptom Inventory | X | Â | Â | X | X | X | X | X |
Medication adverse events | Â | X | X | X | X | X | X | Â |
Alcohol and other drug use | X | Â | Â | X | X | X | X | X |
Urine toxicology tests | X | Â | Â | X | X | Â | X | Â |
Medication adverse events | Â | X | X | X | X | X | X | Â |
Subject reimbursement | Â | Â | Â | Â | Â | Â | Â | Â |
$ Amountc | $15 | $10 | $10 | $15 | $15 | $15 | $15 | $15 |